Compare
Heron Therapeutics, Inc. vs Liquidia Corp vs Macrogenics Inc vs Elite Pharmaceuticals Inc
| Latest fiscal year | Heron Therapeutics, Inc. HRTX | Liquidia Corp LQDA | Macrogenics Inc MGNX | Elite Pharmaceuticals Inc ELTP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $154.90M | $158.32M | $149.50M | $148.87M |
| Revenue growth (YoY) | +7.4% | n/m | -0.3% | +77.1% |
| Gross margin | 73.3% | n/a | n/a | 50.4% |
| Operating margin | -1.6% | -32.5% | -48.7% | 33.0% |
| Net margin | -13.0% | -43.5% | -49.9% | 30.1% |
| Net income | -$20.20M | -$68.92M | -$74.62M | $44.87M |
| EPS (Diluted) | -$0.12 | -$0.80 | -$1.18 | $0.03 |
| Operating cash flow | -$27.59M | -$35.69M | -$81.04M | $23.75M |
| Free cash flow | -$27.91M | -$40.02M | -$82.95M | $22.82M |
| Cash & equivalents | $28.65M | $190.68M | $57.22M | n/a |
| Total assets | $255.88M | $327.93M | $256.85M | $138.29M |
| Total liabilities | $241.54M | $283.19M | $201.25M | $39.41M |
| Shareholders' equity | $14.33M | $44.75M | $55.59M | $98.88M |
| Return on year-end equity | -140.9% | -154.0% | -134.2% | 45.4% |
| Shares outstanding | 188.31M | 87.20M | 63.32M | 1.08B |
Revenue, most recent five fiscal years
| Fiscal year | Heron Therapeutics, Inc. | Liquidia Corp | Macrogenics Inc | Elite Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $154.90M Ended 2025-12-31 | $158.32M Ended 2025-12-31 | $149.50M Ended 2025-12-31 | $148.87M Ended 2026-03-31 |
| 1 year earlier | $144.28M Ended 2024-12-31 | $14.00M Ended 2024-12-31 | $149.96M Ended 2024-12-31 | $84.04M Ended 2025-03-31 |
| 2 years earlier | $127.04M Ended 2023-12-31 | $17.49M Ended 2023-12-31 | $58.75M Ended 2023-12-31 | $56.63M Ended 2024-03-31 |
| 3 years earlier | $107.67M Ended 2022-12-31 | $15.94M Ended 2022-12-31 | $151.94M Ended 2022-12-31 | $34.16M Ended 2023-03-31 |
| 4 years earlier | $86.35M Ended 2021-12-31 | $12.85M Ended 2021-12-31 | $77.45M Ended 2021-12-31 | $32.26M Ended 2022-03-31 |